STROBER, B.; GOTTLIEB, A.; THA?I, D.; PUIG, L.; COLOMBO, M. J.; KUNDU, S.; KISA, R.; BANERJEE, S. An Oral, Selective Tyrosine Kinase 2 Inhibitor, BMS-986165, Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 4, n. 5, p. s27, 2020. DOI: 10.25251/skin.4.supp.27. Disponível em: https://www.jofskin.org/index.php/skin/article/view/976. Acesso em: 5 jul. 2022.